Macquarie Group LTD Travere Therapeutics, Inc. Transaction History

Macquarie Group LTD

$79.1 Billion
Q2 2025

A detailed history of Macquarie Group LTD transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 5,097,482 shares of TVTX stock, worth $117 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

5,097,482

Previous 4,797,314 6.26%

Holding current value

$117 Million

Previous $86 Million 12.24%

% of portfolio

0.1%

Previous 0.11%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$13.49 - $21.54 $4.05 Million - $6.47 Million	300,168 Added 6.26%	5,097,482 $75.4 Million
Q1 2025 May 15, 2025	BUY	$17.07 - $23.75 $9.18 Million - $12.8 Million	537,757 Added 12.62%	4,797,314 $86 Million
Q4 2024 Feb 14, 2025	SELL	$13.65 - $19.85 $182,323 - $265,136	-13,357 Reduced 0.31%	4,259,557 $74.2 Million
Q3 2024 Nov 14, 2024	SELL	$7.89 - $15.21 $748,887 - $1.44 Million	-94,916 Reduced 2.17%	4,272,914 $59.8 Million
Q2 2024 Aug 09, 2024	SELL	$5.26 - $8.28 $1.29 Million - $2.03 Million	-245,229 Reduced 5.32%	4,367,830 $35.9 Million
Q1 2024 May 14, 2024	SELL	$7.18 - $9.82 $960,088 - $1.31 Million	-133,717 Reduced 2.82%	4,613,059 $35.6 Million
Q4 2023 Feb 14, 2024	BUY	$5.44 - $9.5 $407,548 - $711,711	74,917 Added 1.6%	4,746,776 $42.7 Million
Q3 2023 Nov 14, 2023	BUY	$7.64 - $17.25 $5.49 Million - $12.4 Million	718,745 Added 18.18%	4,671,859 $41.8 Million
Q2 2023 Aug 14, 2023	BUY	$15.3 - $22.61 $4.72 Million - $6.97 Million	308,427 Added 8.46%	3,953,114 $60.7 Million
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $1.58 Million - $2.03 Million	88,575 Added 2.49%	3,644,687 $82 Million
Q4 2022 Feb 21, 2023	BUY	$18.47 - $26.14 $4.54 Million - $6.43 Million	245,856 Added 7.43%	3,556,112 $74.8 Million
Q3 2022 Nov 14, 2022	SELL	$22.91 - $28.63 $8.21 Million - $10.3 Million	-358,423 Reduced 9.77%	3,310,256 $81.6 Million
Q2 2022 Aug 15, 2022	BUY	$20.94 - $30.01 $1.17 Million - $1.67 Million	55,778 Added 1.54%	3,668,679 $88.9 Million
Q1 2022 May 16, 2022	SELL	$23.61 - $30.6 $3.66 Million - $4.74 Million	-154,991 Reduced 4.11%	3,612,901 $93.1 Million
Q4 2021 Feb 11, 2022	SELL	$24.34 - $31.17 $4.48 Million - $5.73 Million	-183,949 Reduced 4.65%	3,767,892 $117 Million
Q3 2021 Nov 12, 2021	BUY	$12.98 - $25.03 $511,775 - $986,882	39,428 Added 1.01%	3,951,841 $95.8 Million
Q2 2021 Aug 13, 2021	BUY	$14.11 - $26.4 $16.6 Million - $31 Million	1,174,860 Added 42.92%	3,912,413 $57.1 Million
Q1 2021 May 14, 2021	SELL	$23.37 - $31.77 $616,243 - $837,743	-26,369 Reduced 0.95%	2,737,553 $68.4 Million
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $53 Million - $77 Million	2,763,922 New	2,763,922 $75.3 Million

Others Institutions Holding TVTX

# of Institutions

230

Shares Held

102M

Call Options Held

1.71M

Put Options Held

401K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.48B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Travere Therapeutics, Inc. Transaction History